PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.02%
Revenue growth of 5.02% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
7.85%
Gross profit growth of 7.85% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
14.12%
EBIT growth of 14.12% while Medical - Pharmaceuticals median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
30.87%
Operating income growth of 30.87% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
8.00%
Net income growth of 8.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
8.01%
EPS growth of 8.01% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
8.01%
Diluted EPS growth of 8.01% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.14%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.61%
10Y revenue/share CAGR 1.25-1.5x Medical - Pharmaceuticals median of 1.21%. Mohnish Pabrai would see if consistent reinvestment or product expansions drive this gap.
1.61%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect structural disadvantages or a higher share base limiting per-share growth.
-23.57%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.21%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
No Data
No Data available this quarter, please select a different quarter.
0.22%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper issues limiting long-term profit growth.
0.22%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
-39.53%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.39%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 4.21%. Seth Klarman sees a short-term weakness if peers still expand net worth.
-100.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-100.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-99.58%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-1.78%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
6.99%
Asset growth of 6.99% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.08%
BV/share growth of 4.08% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
10.80%
Debt growth of 10.80% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
63.10%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.